HMGB1 and Sepsis: HMGB1-specific monoclonal antibodies have been demonstrated to be effective for the treatment of a wide range of neuroinflammatory diseases in multiple preclinical models, including stroke [39,40,41,42], traumatic brain injury [43], Parkinson’s disease [44], epilepsy [45,46], autoimmune encephalomyelitis [47,48], Alzheimer’s disease [24], nerve root compression [49], and cognitive decline after sepsis or major surgery [50,51].